Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors

Joint Pain Clinical Trial

Official title: Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors

Status Completed

Clinical Trial Summary

The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.

Clinical Trial Description

This project will determine the efficacy of vitamin D3 supplements for reducing side effects of treatment with aromatase inhibitors in women with a history of breast cancer that have no evidence of current disease. The aromatase inhibitors (AI) have become a critical component of adjuvant therapy for this population, but they cause bone pain, joint pain, joint stiffness, and muscle weakness in approximately 40% of patients. These symptoms, referred to as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), decrease quality of life and medication adherence. Identifying effective ways to decrease these symptoms may allow for longer and more adherent medication use and thus may improve disease-free survival. We hypothesize that vitamin D3 may decrease symptoms associated with the use of aromatase inhibitors. ;

Related Conditions & MeSH terms

• Arthralgia
• Joint Pain
• Muscle Pain
• Myalgia

• NCT number: NCT01509079
• Study type: Interventional
• Source: HealthPartners Institute
• Status: Completed
• Phase: Phase 2
• Start date: March 2012
• Completion date: March 2015